The most common symptoms consist in blurred and distorted vision, black spots in the visual field and a progressive reduction of visual acuity.
Diabetic macular edema: "New therapeutic solutions for a disease that in Italy affects 210 thousand patients, often in both eyes, and which can lead to blindness"
Naples, 16 July 2018 - Propose new clinical-management directions that, while ensuring the sustainability of the national health system, can allow access to the latest therapeutic solutions to all people suffering from retinal diseases, often due to diabetes. This is the aim of the Conference "Retinopathy and diabetic macular edema: innovative diagnostic-therapeutic directions, between integrated management and patient centrality", organized by Ma Provider, thanks to the unconditional contribution of SIFI, with the participation of clinicians, patients , academics and institutions.
"Degenerative diseases of the eye are often related to the evolution of major diseases diagnosed in advanced stages. These diseases represent a serious public health problem, with associated high social costs. Integrated approach, early management and cost reduction of the NHS are the guarantee of a better quality of life for people affected by these diseases ". explained Francesca Simonelli Professor of Ophthalmology, Director of the Ophthalmology Clinic of the University of Campania, L Vanvitelli, President of the Italian Society of Ophthalmology Genetics and Scientific Organizer of the Congress
"Diabetic retinopathy is the leading cause of blindness in working age subjects under 65 and diabetic macular edema is its most important complication. Best treatment available, adherence to therapy and economic-health evaluation are priorities that are impossible to disregard. Drugs that have been on the market in recent years have improved the treatment of this disease ". Said Francesco Rossi, Professor of Pharmacology, "Luigi Vanvitelli" University of Campania and Scientific Coordinator of the Conference.
"The most common symptoms of diabetic macular edema consist in blurred and distorted vision, black spots in the visual field and a progressive reduction of visual acuity. To reduce the risk of blindness from diabetes, innovative intravitreal therapeutic solutions are available that allow, thanks to a slow-release system, both a better adherence of the patient to therapy but above all a significant increase in the quality of life ", specified Teresio Avitabile, SOI Secretary, Director of the University of Ophthalmology "G. Rodolico "of Catania.
"Our mission is to develop, manufacture and market a full range of therapeutic solutions for ophthalmologists and their patients. In this regard, SIFI has recently launched a new treatment on the market for patients with diabetic macular edema which, by virtue of its therapeutic characteristics, we think can give important benefits for the patient both in terms of efficacy and improvement of the quality of life ". Commented Fabrizio Chines, President and CEO of SIFI.